Panelists discuss how emerging targeted agents are poised to reshape the therapeutic landscape for EGFR-mutant NSCLC in the coming years.
Jun Zhang, MD, PhD
Articles by Jun Zhang, MD, PhD
Panelists discuss how proactive sequencing strategies optimize long-term outcomes in EGFR-mutant non–small-cell lung cancer (NSCLC) by anticipating resistance patterns.
Panelists discuss how patient-centered counseling and shared decision-making shape personalized treatment journeys in EGFR-mutant non–small-cell lung cancer (NSCLC).
Panelists discuss how adherence to guidelines and vigilant imaging support optimal management of CNS disease in EGFR-mutant non–small-cell lung cancer.
Panelists discuss how real-world practice blends evidence-based guidance with individualized adjustments for high-risk EGFR-mutant non–small-cell lung cancer (NSCLC) cases.
Panelists discuss how trial data and practical considerations inform the nuanced choice between amivantamab–lazertinib and osimertinib in managing EGFR-mutant non–small-cell lung cancer (NSCLC) with CNS disease.
Panelists discuss how personalized molecular insights drive first-line therapy choices in EGFR-mutant NSCLC with complex metastatic profiles.
